In a correspondence in Nature Medicine an initiative with the aim to connect research with healthcare and establish Sweden as a major player in the field of data-driven precision medicine was presented.

PROMISE (Precision Omics Initiative Sweden) has been developed by leading researchers and clinicians from universities and university hospitals across Sweden with the HPA related professor Jochen Schwenk as part of the Advisory Committee and also one a of the authors of the correspondence. The major goals of this initiative are (1) to generate large-scale multi-omics data with integration of existing research, registry and healthcare data, (2) to maximize research use of omics data created in healthcare and (3) to develop an improved data-access framework.

PROMISE will address diverse disease types including common complex diseases, cancer and rare diseases. To enable prospective intervention studies for evidence-based precision medicine and the possibility to provide patients with access to the latest treatments, a platform will be developed that will be used for both recruitment of trial participants and return of results.

Development and application of diagnostic tools will improve outcome for the diseases in focus and thereby improve population health, while commercialization of these tools and technologies will stimulate the biotech and life sciences sectors and drive economic growth. This initiative therefore has the potential to benefit the Swedish society as a whole.

Link to article